Genmab Reports Positive Results From Three Phase 3 Cancer Drug Trials
Genmab reported positive results from three Phase 3 studies of cancer drugs.
Related stories
Medical Properties Trust Reports Q3 Revenue of $250.1 Million
Medical Properties Trust reported Q3 revenue of $250.1 million, versus a FactSet estimate of $256.9 million.
M impact | EQUITY | Oct 29, 2026, 12:20 PM UTC
IndiGo Executive Sees Stronger Third-Quarter Demand
An IndiGo executive sees much stronger demand in the third quarter compared with the soft second quarter.
M impact | EQUITY | Oct 29, 2026, 12:09 PM UTC
Zhejiang Jingsheng Q3 Net Profit Falls 80.82% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:08 PM UTC
TriMas Reports Q3 Revenue of $178.7M
M impact | EQUITY | Oct 29, 2026, 12:08 PM UTC
Third Space Partners Acquires Quest Events
Third Space Partners acquired Quest Events, which provides live event drape and modular scenic solutions.
M impact | EQUITY | Oct 29, 2026, 12:08 PM UTC
CNX Resources Shares Rise After Q3 Profit and Revenue Beat
CNX Resources shares rose 3.37% in premarket trading after third-quarter core profit and revenue exceeded expectations.
M impact | EQUITY | Oct 29, 2026, 12:07 PM UTC